Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19035781 | Colorectum | SER | regulation of ATP metabolic process | 28/2897 | 87/18723 | 7.51e-05 | 1.68e-03 | 28 |
GO:00463901 | Colorectum | SER | ribose phosphate biosynthetic process | 50/2897 | 190/18723 | 7.70e-05 | 1.72e-03 | 50 |
GO:00060901 | Colorectum | SER | pyruvate metabolic process | 32/2897 | 106/18723 | 9.63e-05 | 2.04e-03 | 32 |
GO:00091851 | Colorectum | SER | ribonucleoside diphosphate metabolic process | 32/2897 | 106/18723 | 9.63e-05 | 2.04e-03 | 32 |
GO:00725221 | Colorectum | SER | purine-containing compound biosynthetic process | 51/2897 | 200/18723 | 1.55e-04 | 3.01e-03 | 51 |
GO:00061641 | Colorectum | SER | purine nucleotide biosynthetic process | 49/2897 | 191/18723 | 1.77e-04 | 3.30e-03 | 49 |
GO:00704821 | Colorectum | SER | response to oxygen levels | 79/2897 | 347/18723 | 1.99e-04 | 3.64e-03 | 79 |
GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
GO:00902571 | Colorectum | SER | regulation of muscle system process | 60/2897 | 252/18723 | 3.28e-04 | 5.22e-03 | 60 |
GO:00060961 | Colorectum | SER | glycolytic process | 25/2897 | 81/18723 | 3.69e-04 | 5.70e-03 | 25 |
GO:00015581 | Colorectum | SER | regulation of cell growth | 90/2897 | 414/18723 | 4.00e-04 | 6.02e-03 | 90 |
GO:00091321 | Colorectum | SER | nucleoside diphosphate metabolic process | 34/2897 | 124/18723 | 4.53e-04 | 6.60e-03 | 34 |
GO:00067571 | Colorectum | SER | ATP generation from ADP | 25/2897 | 82/18723 | 4.54e-04 | 6.60e-03 | 25 |
GO:00193181 | Colorectum | SER | hexose metabolic process | 56/2897 | 237/18723 | 6.19e-04 | 8.42e-03 | 56 |
GO:00016661 | Colorectum | SER | response to hypoxia | 69/2897 | 307/18723 | 7.07e-04 | 9.39e-03 | 69 |
GO:00067341 | Colorectum | SER | NADH metabolic process | 12/2897 | 29/18723 | 7.22e-04 | 9.44e-03 | 12 |
GO:00460311 | Colorectum | SER | ADP metabolic process | 26/2897 | 90/18723 | 8.77e-04 | 1.06e-02 | 26 |
GO:00059961 | Colorectum | SER | monosaccharide metabolic process | 59/2897 | 257/18723 | 9.65e-04 | 1.15e-02 | 59 |
GO:00362931 | Colorectum | SER | response to decreased oxygen levels | 71/2897 | 322/18723 | 1.04e-03 | 1.22e-02 | 71 |
GO:00160491 | Colorectum | SER | cell growth | 100/2897 | 482/18723 | 1.07e-03 | 1.24e-02 | 100 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENO1 | SNV | Missense_Mutation | | c.689C>A | p.Ala230Asp | p.A230D | P06733 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.988) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ENO1 | SNV | Missense_Mutation | rs750183904 | c.466N>A | p.Gly156Ser | p.G156S | P06733 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.594) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ENO1 | insertion | Nonsense_Mutation | novel | c.945_946insATTTTATTTTTATTTTTTTGAGAGGGATCTCACTC | p.Val316IlefsTer7 | p.V316Ifs*7 | P06733 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ENO1 | SNV | Missense_Mutation | | c.1240G>A | p.Glu414Lys | p.E414K | P06733 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.984) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | | SD |
ENO1 | SNV | Missense_Mutation | rs527568599 | c.452N>G | p.Asn151Ser | p.N151S | P06733 | protein_coding | deleterious_low_confidence(0.05) | benign(0.083) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ENO1 | SNV | Missense_Mutation | novel | c.628N>A | p.Glu210Lys | p.E210K | P06733 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.796) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ENO1 | insertion | Frame_Shift_Ins | novel | c.1081dupC | p.Gln361ProfsTer17 | p.Q361Pfs*17 | P06733 | protein_coding | | | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ENO1 | SNV | Missense_Mutation | novel | c.97G>C | p.Ala33Pro | p.A33P | P06733 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
ENO1 | SNV | Missense_Mutation | | c.223C>G | p.Pro75Ala | p.P75A | P06733 | protein_coding | deleterious_low_confidence(0.03) | benign(0.046) | TCGA-AD-6965-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | PD |
ENO1 | SNV | Missense_Mutation | | c.1286G>A | p.Arg429Lys | p.R429K | P06733 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.861) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |